Three-Year Data from Oraya Therapeutics’ INTREPID Study Continue to Show Favorable Safety Profile of Non-Invasive Wet AMD Therapy
September 13, 2014Oraya Therapeutics announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for Wet AMD demonstrated a favorable safety profile.
More »
Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management
September 11, 2014Orexigen® Therapeutics and Takeda Pharmaceuticals announced the U.S. FDA's approval of Contrave® extended-release tablets for chronic weight management in obese and overweight adults.
More »
Colorescience Announces Successful Completion Of $15 Million Series B Preferred Stock Offering
September 10, 2014Colorescience announced the completion of a $15 million Series B Preferred Stock Offering at $1.14 per share. The round was lead by Longwood Fund.
More »